Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of H.U. Group Holdings, Inc.. A complete text table follows the diagram.
Clinical testing improved JPY2B, but diagnostics remained the profit engine and acquisition costs reduced its earnings.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| In Vitro Diagnostics Business | 1 | 4.8B | 80.6% of reported total |
| Sterilization & related services | 1 | 1.2B | 19.4% of reported total |
| Gross operating income | 2 | 6.0B | Reported six-month total · ¥6.0B |
| Operating Income | 3 | 2.3B | Reported consolidated total |
| Eliminations & reconciliation | 3 | 3.7B | Reported dimensional reconciliation |
| From | To | Value |
|---|---|---|
| In Vitro Diagnostics Business | Gross operating income | 4.8B |
| Sterilization & related services | Gross operating income | 1.2B |
| Gross operating income | Operating Income | 2.3B |
| Gross operating income | Eliminations & reconciliation | 3.7B |